Meeting
2013 ASCO Annual Meeting
A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer.
Authors
Roopa Lakhanpal
Department of Medical Oncology, The Canberra Hospital, Canberra, Australia
Roopa Lakhanpal , Robin Stuart-Harris , Arlene Chan , Dusan Kotasek , Jane McNeil Beith , Katharine Cuff , Patricia A. Bastick , Clara Inkyung Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1079)
DOI
10.1200/jco.2013.31.15_suppl.1079
Abstract #
1079
Poster Bd #
23F
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).
First Author: Douglas W. Blayney
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2012 Breast Cancer Symposium
Adjuvant chemotherapy for early-stage breast cancer: Choice of regimen and associated hematologic toxicities in a metropolitan Australian hospital.
First Author: Katherine Lovat
Poster
2011 ASCO Annual Meeting
Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic.
First Author: A. Soni